Literature DB >> 22232714

Clinical analysis of acinic cell carcinoma in parotid gland.

Wonjae Cha1, Min-Su Kim, Jae-Chul Ahn, Sung-Woo Cho, Woongsang Sunwoo, Chang Myeon Song, Tack-Kyun Kwon, Myung-Whun Sung, Kwang Hyun Kim.   

Abstract

OBJECTIVES: Acinic cell carcinoma (AciCC) is a rarely encountered malignancy in parotid gland. Because AciCC is rare and was recently recognized as the entity of malignancy, AciCC has been difficult to study. We aimed to analyze the diagnosis and treatment experience for this malignancy in our hospital.
METHODS: We retrospectively reviewed medical records of the 20 patients with AciCC of parotid gland diagnosed from 1990 to 2009. The preoperative computed tomography scan, preoperative fine needle aspiration cytology (FNAC) and intraoperative frozen section results were compared with the final diagnosis. The survival and recurrence were analyzed with the cancer stages and treatment modalities.
RESULTS: There were 10 males and 10 females, with a mean age of 44.4 years, ranging 8-77 years. The AJCC tumor stage distributions of the patients were 70%, 15%, and 15% for stages I, II, and IV, respectively. The sensitivity of FNAC and intraoperative frozen section was 26.7% and 50.0% respectively. The 10-year survival rate was 90.9% with a mean follow-up of 111 months, ranging 17-251 months. The 10-year disease free survival rate was 74.2% and the mean duration of recurrence from initial surgery was 92.3 months.
CONCLUSION: AciCC of the parotid gland is a rare malignancy that has features of less aggressive behavior, and good prognosis. Intraoperative frozen section examination may be helpful in the diagnosis of AciCC of the parotid gland because of the low sensitivity of preoperative computed tomography scan and FNAC. Surgery with adjuvant postoperative radiotherapy is satisfactory for disease control.

Entities:  

Keywords:  Acinic cell carcinoma; Parotid neoplasms; Salivary gland neoplasms

Year:  2011        PMID: 22232714      PMCID: PMC3250583          DOI: 10.3342/ceo.2011.4.4.188

Source DB:  PubMed          Journal:  Clin Exp Otorhinolaryngol        ISSN: 1976-8710            Impact factor:   3.372


  24 in total

1.  Tumors of the major salivary glands.

Authors:  F W FOOTE; E L FRAZELL
Journal:  Cancer       Date:  1953-11       Impact factor: 6.860

2.  Metastatic acinic cell carcinoma of the parotid gland with ectopic ACTH syndrome.

Authors:  Lucy Jamieson; S Mark Taylor; Anita Smith; Martin J Bullock; Mary Davis
Journal:  Otolaryngol Head Neck Surg       Date:  2007-01       Impact factor: 3.497

3.  Clinico-pathological predictors of recurrence for acinic cell carcinoma.

Authors:  C I Timon; I Dardick; T Panzarella; J Thomas; G Ellis; P Gullane
Journal:  Clin Otolaryngol Allied Sci       Date:  1995-10

4.  Acinic cell carcinoma of the parotid gland.

Authors:  C M Eneroth; P A Jakobsson; C Blanck
Journal:  Cancer       Date:  1966-12       Impact factor: 6.860

5.  Retrospective analysis of 35 patients with acinic cell carcinoma of the parotid gland.

Authors:  R Laskawi; R Rödel; A Zirk; C Arglebe
Journal:  J Oral Maxillofac Surg       Date:  1998-04       Impact factor: 1.895

6.  Acinic cell carcinoma of the parotid gland: a 15-year review limited to a single surgeon at a single institution.

Authors:  S Alex Kim; Robert H Mathog
Journal:  Ear Nose Throat J       Date:  2005-09       Impact factor: 1.697

7.  Carcinoma of the parotid gland.

Authors:  Peter Zbären; Jonas Schüpbach; Michel Nuyens; Edouard Stauffer; Richard Greiner; Rudolf Häusler
Journal:  Am J Surg       Date:  2003-07       Impact factor: 2.565

8.  Acinic cell carcinoma of the parotid gland: Auckland experience and literature review.

Authors:  Samuel R Greig; John M Chaplin; Nicholas P McIvor; Mark E Izzard; Graham Taylor; Desmond Wee
Journal:  ANZ J Surg       Date:  2008-09       Impact factor: 1.872

9.  Acinic cell carcinoma of the parotid gland: review and management.

Authors:  P D Spafford; D R Mintz; J Hay
Journal:  J Otolaryngol       Date:  1991-08

10.  Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland.

Authors:  Daniel R Gomez; Nora Katabi; Joanne Zhung; Suzanne L Wolden; Michael J Zelefsky; Dennis H Kraus; Jatin P Shah; Richard J Wong; Ronald A Ghossein; Nancy Y Lee
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

View more
  5 in total

Review 1.  Salivary acinic cell carcinoma: reappraisal and update.

Authors:  V Vander Poorten; A Triantafyllou; L D R Thompson; J Bishop; E Hauben; J Hunt; A Skalova; G Stenman; R P Takes; D R Gnepp; H Hellquist; B Wenig; D Bell; A Rinaldo; A Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-19       Impact factor: 2.503

2.  Postoperative [¹²⁵I] seed brachytherapy in the treatment of acinic cell carcinoma of the parotid gland: with associated risk factors.

Authors:  Ming-Hui Mao; Jian-Guo Zhang; Jie Zhang; Lei Zheng; Shu-Ming Liu; Ming-Wei Huang; Yan Shi
Journal:  Strahlenther Onkol       Date:  2014-04-29       Impact factor: 3.621

3.  Ectopic Cushing's Syndrome Unveiling a Metastatic Parotid Carcinoma.

Authors:  Sofia Castro Oliveira; João Sérgio Neves; Pedro Souteiro; Sandra Belo; Ana Isabel Oliveira; Helena Moreira; Paulo Mergulhão Gomes; Lígia Coelho; Cristina Sarmento; Elsa Fonseca; Celestino Neves; Paula Freitas; Davide Carvalho
Journal:  Case Rep Endocrinol       Date:  2019-10-15

4.  Ectopic ACTH Production Caused by Metastatic Parotid Gland Acinic Cell Carcinoma.

Authors:  Jacob M Burch; James S Choi; Osama Mosalem; Lawrenshey Charles
Journal:  AACE Clin Case Rep       Date:  2021-01-08

Review 5.  Estimating survival after salvage surgery for recurrent salivary gland cancers: Systematic review.

Authors:  Giuditta Mannelli; Lara V Comini; Andrea Sacchetto; Roberto Santoro; Giuseppe Spinelli; Pierluigi Bonomo; Isacco Desideri; Paolo Bossi; Ester Orlandi; Giammarco Alderotti; Alessandro Franchi; Annarita Palomba; Albino Eccher; Daniele Marchioni; Riccardo Nocini; Cesare Piazza; Gabriele Molteni
Journal:  Head Neck       Date:  2022-04-20       Impact factor: 3.821

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.